1. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, et al. 2020 International Society Of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020; 75(6): 1334-1357. https://www.ahajournals.org/doi/full/10.1161/HYPERTENSIONAHA.120.15026
2. Cicero AFG, Landolfo M, Borghi C. Are monotherapies still valuable to the treatment of hypertension? Expert Opin Pharmacother. 2020; 21(13): 1523-1526. doi: 10.1080/14656566.2020.1770728. https://www.tandfonline.com/doi/full/10.1080/14656566.2020.1770728
3. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, et al. 2023 ESH Guidelines For The Management Of Arterial Hypertension The Task Force For The Management Of Arterial Hypertension Of The European Society Of Hypertension Endorsed By The International Society Of Hypertension (ISH) And The European Renal Association (ERA). J Hypertens. 2023. Doi: 10.1097/HJH.0000000000003480. https://journals.lww.com/jhypertension/fulltext/2023/12000/2023_esh_guidelines_for_the_management_of_arterial.2.aspx
4. Shrimpton AJ, Walker SLM, Ackland GL. Angiotensin Converting Enzyme Inhibitors And Angiotensin Receptor Blockers. BJA Educ. 2020; 20(11): 362-367. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7808101/
5. Ram CV. Angiotensin receptor blockers: current status and future prospects. Am J Med. 2008; 121(8):656-63. doi: 10.1016/j.amjmed.2008.02.038. PMID: 18691475. https://www.amjmed.com/article/S0002-9343(08)00297-0/fulltext
6. Zhu J, Chen N, Zhou M, Guo J, Zhu C, Zhou J, Ma M, He L. Calcium Channel Blockers Versus Other Classes Of Drugs For Hypertension. Cochrane Database Syst Rev. 2022; 1(1): CD003654. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8742884/
7. Wu L, Deng SB, She Q. Calcium Channel Blocker Compared With Angiotensin Receptor Blocker For Patients With Hypertension: A Meta-Analysis Of Randomized Controlled Trials. J Clin Hypertens. 2014; 16(11): 838-45. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8031805/
8. Lin YC, Lin JW, Wu MS, Chen KC, Peng CC, et al. Effects Of Calcium Channel Blockers Comparing To Angiotensin-Converting Enzyme Inhibitors And Angiotensin Receptor Blockers In Patients With Hypertension And Chronic Kidney Disease Stage 3 To 5 And Dialysis: A Systematic Review And Meta-Analysis. Plos One. 2017; 12(12): E0188975. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730188/
9. Park C, Wang G, Durthaler JM, Fang J. Cost-Effectiveness Analyses Of Antihypertensive Medicines: A Systematic Review. Am J Prev Med. 2017; 53(6S2): S131-S142. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5836308/
10. Jackson BE, Bellamny MC. Antihypertensive Drug. BJA Education. 2015. 15 (6): 280–285. https://academic.oup.com/bjaed/article/15/6/280/356246
11. Gallo G, Volpe M, Rubattu S. Angiotensin Receptor Blockers In The Management Of Hypertension: A Real-World Perspective And Current Recommendations. Vasc Health Risk Manag. 2022; 18: 507-515. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285525/